
**UPDATE TO SHAREHOLDERS ON PROCEEDINGS COMMENCED BY WEIXIN HOSPITAL
INVESTMENT MANAGEMENT (SHANGHAI) CO. LTD.**

The Board of Directors (“**Board**”) of OUE Lippo Healthcare Limited (“**Company**”, and together with its subsidiaries, the “**Group**”) refers to the Company’s announcements dated 20 December 2017 and 6 August 2018 (the “**August 18 Update Announcement**”) in relation to the proceedings brought by one Weixin Hospital Investment Management (Shanghai) Co. Ltd (卫心医院投资管理 (上海) 有限公司) (“**Weixin**”), which is a company controlled by one Mr David Lin Kao Kun, against Shanghai Yi Lin Medical Management Consulting Co., Ltd (上海医霖医疗管理咨询有限公司) (“**Shanghai Yilin**”) and Wuxi New District Phoenix Hospital Co., Ltd (无锡新区凤凰医院有限责任公司) (“**Wuxi Co.**”), as defendants, and Healthkind Investment Management Consulting Co. Ltd (上海医霖医院投资管理咨询有限公司) (“**Healthkind Shanghai**”), as third party, before the Shanghai Courts. In particular, the appeal Court had decided the matter in favour of Weixin, but the Company has given instructions to its PRC Counsel to file an application for retrial before the Shanghai High Court.

As stated in the August 18 Update Announcement, whilst Wuxi Co. holds the hospital license for and operates Wuxi New District Phoenix Hospital (“**Hospital**”), the interests in the medical equipment, land and building (“**Hospital Properties**”) on and in which the Hospital is located are separately owned and held by another subsidiary of the Company, namely Wuxi Yilin Real Estate Development Co Ltd (无锡医霖置业发展有限公司) (“**Wuxi Yilin Real Estate**”).

The Board wishes to update the Company’s shareholders that the Company has been informed by the PRC Counsel today that Weixin has recently commenced legal proceedings against Wuxi Yilin Real Estate and Wuxi Co., seeking to declare a land transfer agreement between Wuxi Yilin Real Estate and Wuxi Co. dated 15 January 2015 to be void. The Group has been advised by its PRC Counsel that there is no merit in Weixin’s claim and has instructed its PRC Counsel to vigorously defend these proceedings.

The Board will also make further announcements to update the Company’s shareholders as and when there are any further material developments.

By Order of the Board

Dr Wong Weng Hong
Chief Executive Officer and Executive Director
23 August 2018

*This announcement has been prepared by OUE Lippo Healthcare Limited (formerly known as International Healthway Corporation Limited) (the “**Company**”) and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”), for compliance with the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).